Page last updated: 2024-11-07

spironolactone and Debility

spironolactone has been researched along with Debility in 1 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Research Excerpts

ExcerptRelevanceReference
"The impact of frailty on outcomes in randomized heart failure with preserved ejection fraction (HFpEF) trials has not been previously reported."2.87The frailty syndrome and outcomes in the TOPCAT trial. ( Claggett, B; Desai, AS; Fang, JC; Lewis, EF; Liu, J; Pfeffer, MA; Sanders, NA; Solomon, SD; Supiano, MA; Sweitzer, NK, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sanders, NA1
Supiano, MA1
Lewis, EF1
Liu, J1
Claggett, B1
Pfeffer, MA1
Desai, AS1
Sweitzer, NK1
Solomon, SD1
Fang, JC1

Trials

1 trial available for spironolactone and Debility

ArticleYear
The frailty syndrome and outcomes in the TOPCAT trial.
    European journal of heart failure, 2018, Volume: 20, Issue:11

    Topics: Aged; Americas; Double-Blind Method; Female; Frail Elderly; Frailty; Georgia (Republic); Heart Failu

2018